Core Viewpoint - Lexeo Therapeutics has released interim data from the Phase I/II clinical trial of LX2020, aimed at treating PKP2-associated arrhythmogenic cardiomyopathy (ACM) [2]. Group 1: Clinical Trial Update - The interim data from the Lexeo HEROIC-PKP2 clinical trial of LX2020 has been made available, indicating progress in the treatment of PKP2-associated ACM [2]. - The press release detailing the interim data update can be found on Lexeo's website, along with presentation slides related to the call [2]. Group 2: Leadership Involvement - The conference call features key executives including Nolan Townsend, Chief Executive Officer, and Dr. Eric Adler, Head of Research, highlighting the company's leadership in discussing the trial results [2].
Lexeo Therapeutics, Inc. (LXEO) Discusses Preliminary Data From Phase I/II Trial of LX2020 for PKP2-Associated Arrhythmogenic Cardiomyopathy Transcript